Why the study?
Does azilsartan medoxomil and chlorthalidone fixed-dose combination improve antihypertensive efficacy compared to olmesartan and hydrochlorothiazide in patients with stage-2 systolic hypertension?
Does azilsartan medoxomil and chlorthalidone fixed-dose combination improve antihypertensive efficacy compared to olmesartan and hydrochlorothiazide in patients with stage-2 systolic hypertension?
Azilsartan medoxomil/chlorthalidone fixed-dose combination is more effective at lowering blood pressure than maximum-dose olmesartan/hydrochlorothiazide in stage-2 systolic hypertension.
Answers are grounded in this paper and cite their sources.
Supports AZL-M/CTD FDCs over max-dose OLM/HCTZ for stage-2 systolic hypertension; extends comparative ARB-diuretic FDC data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cushman et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: